R01TW012674

Reducing stigma in people who inject drugs with HIV using a rapid start antiretroviral therapy intervention - HIV transmission continues in low- and middle-income countries (LMIC), especially among key affected populations (KAP) and in settings of high stigma and discrimination.

In Malaysia, a LMIC in SE Asia, HIV incidence and mortality is increasing. HIV is concentrated among KAPs, especially people who inject drugs (PWID), a group that has substantially lower ART prescription and viral suppression (VS) levels relative to other KAPs, undermining HIV treatment as prevention (TASP) goals.

PWID are especially vulnerable to overlapping and intersectional stigmas due to criminalization of drug use and sex work, experiences with incarceration, social class, and the presence of HIV itself.

Our preliminary studies confirm high levels of negative stereotypes, prejudice, and stigma toward PWID among medical students and HIV experts, with clear evidence of intention to discriminate against PWID by withholding ART prescription.

Stigma-reducing interventions have mostly centered on educational and contact-based strategies. Such strategies, however, appear less effective where stereotypes and stigma are deeply entrenched, as in Malaysia, thus requiring the introduction and testing of alternative strategies.

Behavioral design interventions are potentially effective ways to address stigma in such settings. Behavioral design interventions use tools like framing, nudges, and choice architecture, which can be used to re-design how physicians behave – or make non-discriminatory healthcare decisions.

Rapid start antiretroviral (RS-ART) is an evidence-based strategy to initiate ART immediately, thereby supporting TASP goals by reducing time to VS, achieving VS, and improving individual health. It has not been tested among PWID.

It fits the criteria for behavioral design interventions by re-arranging clinician decision-making by first focusing on eligibility criteria (i.e., presence of opportunistic infections) rather than inaccurate perceptions of ART adherence or deservedness.

Behavioral design interventions have not been tested in HIV stigma research, nor have they been assessed longitudinally or infusing clinically relevant dyads analyses of patients and clinicians.

To guide the behavioral design of RS-ART among PWID, we will use the Delphi method to develop guidelines. Then we will use nominal group technique, a rank-ordering mixed method strategy to assess the multi-level barriers and facilitators to RS-ART for PWID, in order to adapt existing RS-ART protocols for PWID.

Once the new guideline concordant RS-ART protocol is developed, we will pilot test it in 125 PWID over six months and conduct a longitudinal dyadic analysis of patients and clinicians of stigma, physician trust, and social support.

The RS-ART protocol will be refined further during pilot-testing to determine its utility as a stigma-reducing intervention that can be tested in a future implementation trial.

This proposal brings over 17 years of productive collaboration between Yale and University of Malaya, with expertise in clinical HIV and addiction treatment, participation in clinical guidelines development, mixed methods research, intervention development and refinement, multi-level stigma assessment and intervention, and dyadic analyses.

Yale Univ

THE JOHN E. FOGARTY INTERNATIONAL CENTER (FIC) SUPPORTS RESEARCH AND RESEARCH TRAINING TO REDUCE DISPARITIES IN GLOBAL HEALTH AND TO FOSTER PARTNERSHIPS BETWEEN U.S. SCIENTISTS AND THEIR COUNTERPARTS ABROAD. FIC SUPPORTS BASIC BIOLOGICAL, BEHAVIORAL, AND SOCIAL SCIENCE RESEARCH, AS WELL AS RELATED RESEARCH TRAINING AND CAREER DEVELOPMENT. THE RESEARCH PORTFOLIO IS DIVIDED INTO SEVERAL PROGRAMS THAT SUPPORT A WIDE VARIETY OF FUNDING MECHANISMS TO MEET PROGRAMMATIC OBJECTIVES.

93.279 - Drug Abuse and Addiction Research Programs

Fogarty International Center (FIC) [HHS - NIH]

National Institute on Drug Abuse (NIDA) [HHS - NIH]

New Haven, Connecticut 065102483 United States

Single Zip Code

Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries (R01 - Clinical Trial Optional) (PAR-21-344)

Amendment Since initial award the total obligations have increased 317% from $170,262 to $709,550.